This segment of a Q&A interview with Kilian Eyerich, MD, PhD, highlights the signficance of the LumiNE phase 3 study on lebrikizumab.
Kilian Eyerich, MD, PhD
Advertisement
Kilian Eyerich, MD, PhD, is chair and professor at the Department of Dermatology and Venerology of the University of Freiburg, Germany, as well as a guest professor at the Karolinska Institute in Stockholm, Sweden.
Articles by Kilian Eyerich, MD, PhD
A new phase 3 study is evaluating lebrikizumab in at least 270 patients with nummular eczema over 48 weeks.
Advertisement
Latest Updated Articles
Advertisement
Advertisement